0.021
0.00 (0.00%)
| Penutupan Terdahulu | 0.021 |
| Jumlah Dagangan | 3,540,674 |
| Harga / Jualan (P/S) | 104.89 |
| Harga / Buku (P/B) | 44.57 |
| Julat 52 Minggu |
| Margin Keuntungan | -275.64% |
| Margin Operasi (TTM) | -109.11% |
| EPS Cair (TTM) | 0.000 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2,926.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 32.93% |
| Nisbah Semasa (MRQ) | 2.81 |
| Aliran Tunai Operasi (OCF TTM) | -3.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.85 M |
| Pulangan Atas Aset (ROA TTM) | -31.11% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AVECHO FPO [AVE] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 3.0 |
| Purata | 0.50 |
|
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 35.82% |
| % Dimiliki oleh Institusi | 3.18% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |